All patients with metastatic lung, colorectal, pancreatic or head and neck cancers who
initially benefit from epidermal growth factor receptor (EGFR)-targeted therapies eventually …

The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational
development of targeted drugs for patient populations stratified by genetic characteristics …

Background Patients with metastatic colorectal cancer that harbors KRAS mutations in exon
2 do not benefit from anti–epidermal growth factor receptor (EGFR) therapy. Other activating …

Background Patients with advanced gastric cancer have a poor prognosis and few
efficacious treatment options. We aimed to assess the addition of cetuximab to capecitabine …

Purpose To assess the effects of cetuximab plus chemotherapy as first-line treatment for
unresectable colorectal liver metastases (CLMs). Patients and Methods After resection of …

Background Therapeutic antibodies targeting EGFR have activity in advanced colorectal
cancer, but results from clinical trials are inconsistent and the population in which most …

Consensus abstract Background The management of primary rectal cancer beyond total
mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging …

Purpose Early tumor shrinkage (ETS) is associated with long-term outcome in patients with
chemorefractory metastatic colorectal cancer (mCRC) receiving cetuximab. This association …

In metastatic colorectal cancer (mCRC), an improved understanding of the underlying
pathology and molecular biology has successfully merged with advances in diagnostic …

OBJECTIVES: Microsatellite instability (MSI) is an established marker of good prognosis in
colorectal cancer (CRC). Chromosomal instability (CIN) is strongly negatively associated …